Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Călugăru D, Călugăru M . Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA. Eye (Lond) 2017; 31: 1112–1113.
Lotery AJ, Regnier S . Patterns of ranibizumab and aflibercept treatment of central retinal vein occlusion in routine clinical practice in the USA. Eye (Lond) 2015; 29: 380–387.
Călugăru D, Călugăru M . Patterns of ranibizumab and aflibercept treatment of central retinal vein occlusion in routine clinical practice in the USA. Eye (Lond) 2015; 29: 1113.
Lotery A, Regnier S . Response to ‘Patterns of ranibizumab and aflibercept treatment of central retinal vein occlusion in routine clinical practice in the USA'. Eye (Lond) 2015; 29 (8): 1113–1114.
Nghiem-Buffet S, Baillif S, Regnier S, Skelly A, Yu N, Sodi A . Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA. Eye (Lond) 2017; 31: 551–559.
Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N et al. Ranibizumab for macular edema following central retinal vein occlusion. six-month primary end point results of a phase III study. Ophthalmology 2010; 117: 1124–1133.
Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N et al for the BRAVO Investigators. Ranibizumab for macular edema following branch retinal vein occlusion. six-month primary end point results of a phase III study. Ophthalmology 2010; 117: 1102–1112.
Callanan DG, Loewenstein A, Patel SS, Massin P, Corcostegui B, Li XT et al. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2016. e-pub ahead of print 8 September 2016.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
SN-B and SB are consultants for Allergan, Bayer and Novartis. SR is an employee of Novartis Pharma AG, Basel, Switzerland. A Skelly is an employee of Novartis Pharma AG, Basel, Switzerland. NY was an employee of IMS Health, London, UK, at the time of the original study, funded by Novartis to perform the statistical analyses for the study, but was not involved in the collection of the dataset or in gaining access to it for the purposes of the study. A Sodi is a member of the Novartis RVO advisory board.
Rights and permissions
About this article
Cite this article
Nghiem-Buffet, S., Baillif, S., Regnier, S. et al. Response to Comment on: Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA. Eye 31, 1113–1114 (2017). https://doi.org/10.1038/eye.2017.15
Published:
Issue date:
DOI: https://doi.org/10.1038/eye.2017.15
